생물학적 사전 지식을 활용한 고차원의 다중 오믹스 관계를 찾는 컴퓨터 공학적 접근 방법

학위논문(박사) -- 서울대학교대학원 : 공과대학 컴퓨터공학부, 2021.8. 김선.세포가 어떻게 기능하고 외부 자극에 반응하는지 이해하는 것은 생물학, 의학에서 가장 중요한 관심사 중 하나이다. 기술의 발전으로 과학자들은 단일 생물학적 실험으로 세포의 변화요인들을 쉽게 측정할 수 있게 되었다. 주목할만한 예시로 게놈 시퀀싱, 유전자 발현량 측정, 유전자 발현을 조절하는 후성 유전체 측정 같은 다중 오믹스 데이터가 있다. 세포의 상태를 더 자세히 이해하기 위해서 다중 오믹스 조절자와 유전자 사이의 조절 관계를 알아내는 것이 중요하다. 하지만 다중 오믹스 조절 관계는 매우 복잡하고 모든 세포 상태 특이적인 관계를 실험적으로 검증하는 것은 불가능하다. 따라서, 서로 다른 유형의 고차원 오믹스 데이터로부터 관계를 예측하기 위한 효율적인 컴퓨터 공학적 접근방법이 요구된다. 이러한 고차원 데이터를 처리하는 한 가지 방법은 다양한 데이터베이스에서 선별된 유전자의 기능과 오믹스 간의 관계와 같은 외부 생물학적 지식을 통합하여 활용하는 것이다. 본 박사학위 논문은 생물학적 사전 지식을 활용하여 다중 오믹스 데이터로부터 유전자의 발현을 조절하는 관계를 예측하기 위한 세 가지 컴퓨터 공학적인 접근법을 제안하였다. 첫 번째는 마이크로 알엔에이와 유전자의 일대다 관계를 예측하기 위한 기법이다. 마이크로 알엔에이 표적 예측 문제는 가능한 표적 유전자의 개수가 너무 많으며 거짓 양성과 거짓음성의 비율을 조절해야 하는 문제가 있다. 이러한 문제를 해결하기 위해 마이크로 알엔에이-유전자와 데이터의 맥락 사이의 연관성을 문헌 지식을 활용하여 결정하고 마이크로 알엔에이-유전자 관계를 예측하기 위한 ContextMMIA를 개발하였다. ContextMMIA는 통계적 유의성과 문헌 관련성을 기반으로 마이크로 알엔에이-유전자 관계의 점수를 계산하여 관계의 우선순위를 결정한다. 예후가 다른 유방암 데이터에 대한 실험에서 ContextMMIA는 예후가 나쁜 유방암에서 활성화된 마이크로 알엔에이-유전자 관계를 예측하였고 기존 실험적으로 검증된 관계가 높은 우선순위로 예측되었으며 해당 유전자들이 유방암 관련 경로에 관여하는 것으로 알려졌다. 두 번째는 약물 반응을 일으키는 유전자의 다대일 조절 관계를 예측하기 위한 기법이다. 약물 반응 예측을 위해서 약물 반응 매개 유전자를 결정해야 하며 이를 위해 20,000개 유전자의 다중 오믹스 데이터를 통합 분석하는 방법이 필요하다. 이 문제를 해결하기 위해 저차원 임베딩 방법, 약물-유전자 연관성에 대한 문헌 지식 및 유전자-유전자 상호 작용 지식을 활용하여 약물 반응을 예측하기 위한 DRIM을 개발하였다. DRIM은 오토인코더, 텐서 분해, 약물-유전자 연관성을 이용하여 다중 오믹스 데이터에서 다대일 관계를 결정한다. 결정된 매개 유전자의 조절 관계를 유전자-유전자 상호 작용 지식과 약물 반응 시계열 유전자 발현 데이터의 상호 상관관계를 이용하여 결정한다. 유방암 세포주 데이터에 대한 실험에서 DRIM은 라파티닙이 표적으로 하는 PI3K-Akt 패스웨이에 관여하는 유전자들의 약물 반응 조절 관계를 예측하였고 라파티닙 반응성과 관련된 매개 유전자를 예측하였다. 그리고 예측된 조절 관계가 세포주 특이적인 패턴을 보이는 것을 확인하였다. 세 번째는 세포의 상태를 설명하는 조절자와 유전자의 다대다 조절 관계를 예측하기 위한 기법이다. 다대다 관계 예측을 위해 관찰된 유전자 발현 값과 유전자 조절 네트워크로부터 추정된 유전자 발현 값 사이의 차이를 측정하는 목적 함수를 만들었다. 목적 함수를 최소화하기 위하여 조절인자와 유전자의 수에 따라 기하급수적으로 증가하는 검색 공간을 탐색해야 한다. 이 문제를 해결하기 위해 조절자-유전자 상호 작용 지식을 활용하여 두 가지 연산을 반복하여 조절 관계를 찾는 최적화 기법을 개발하였다. 첫 번째 단계는 네트워크에 간선을 추가하기 위해 강화 학습 기반 휴리스틱을 통해 조절자를 선택하는 다대일 유전자 중심 관계를 탐색하는 단계이다. 두 번째 단계는 네트워크에서 간선을 제거하기 위해 유전자를 확률적으로 선택하는 일대다 조절자 중심 관계를 탐색하는 단계이다. 유방암 세포주 데이터에 대한 실험에서 제안된 방법은 이전의 최적화 방법보다 더 정확한 유전자 발현량 추정을 하였고 조절자 및 유전자 발현 데이터로 유방암 아형 특이적 네트워크를 구성하였다. 또한, 유방암 아형 관련 실험 검증된 조절 관계를 예측하였다. 요약하면, 본 박사학위 논문은 다중 오믹스 조절자와 유전자의 사이의 일대다, 다대일, 다대다 관계를 예측하기 위하여 생물학적 지식을 활용한 컴퓨터 공학적 접근법을 제안하였다. 제안된 방법은 증가하고 있는 분자 생물학 데이터를 분석하여 유전자 조절 상호 작용을 이해함으로써 세포 기능에 대한 심층적인 이해를 도와줄 수 있을 것으로 기대된다.Understanding how cells function or respond to external stimuli is one of the most important questions in biology and medicine. Thanks to the advances in instrumental technologies, scientists can routinely measure events within cells in single biological experiments. Notable examples are multi-omics data: sequencing of genomes, quantifications of gene expression, and identification of epigenetic events that regulate expression of genes. In order to better understand cellular mechanisms, it is essential to identify regulatory relationships between multi-omics regulators and genes. However, regulatory relationships are very complex and it is infeasible to validate all condition-specific relationships experimentally. Thus, there is an urgent need for an efficient computational method to extract relationships from different types of high-dimensional omics data. One way to address these high-dimensional data is to incorporate external biological knowledge such as relationships between omics and functions of genes curated in various databases. In my doctoral study, I developed three computational approaches to identify the regulatory relationships from multi-omics data utilizing biological prior knowledge. The first study proposes a method to predict one-to-m relationships between miRNA and genes. The computational challenge of miRNA target prediction is that there are many miRNA target candidates, and the ratio of false positives to false negatives needs to be adjusted. This challenge is addressed by utilizing literature knowledge for determining the association between miRNA-gene and a given context. In this study, I developed ContextMMIA to predict miRNA-gene relationships from miRNA and gene expression data. ContextMMIA computes scores of miRNA-gene relationships based on statistical significance and literature relevance and prioritizes the relationships based on the scores. In experiments on breast cancer data with different prognosis, ContextMMIA predicted differentially activated miRNA-gene relationships in invasive breast cancer. The experimentally verified miRNA-gene relationships were predicted with high priority and those genes are known to be involved in breast cancer-related pathways. The second study proposes a method to predict n-to-one relationships between regulators and gene on drug response. The computational challenge of drug response prediction is how to integrate multi-omics data of 20,000 genes for determining drug response mediator genes. This challenge is addressed by utilizing low-dimensional embedding methods, literature knowledge of drug-gene associations, and gene-gene interaction knowledge. For this problem, I developed DRIM to predict drug response relationships from the multi-omics data and drug-induced time-series gene expression data. DRIM uses autoencoder, tensor decomposition, and drug-gene association to determine n-to-one relationships from multi-omics data. Then, regulatory relationships of mediator genes are determined by gene-gene interaction knowledge and cross-correlation of drug-induced time-series gene expression data. In experiments on breast cancer cell line data, DRIM extracted mediator genes relevant to drug response and regulatory relationships of genes involved in the PI3K-Akt pathway targeted by lapatinib. In addition, DRIM revealed distinguished patterns of relationships in breast cancer cell lines with different lapatinib resistance. The third study proposes a method to predict n-to-m relationships between regulators and genes. In order to predict n-to-m relationships, this study formulated an objective function that measures the deviation between observed gene expression values and estimated gene expression values derived from gene regulatory networks. The computational challenge of minimizing the objective function is to navigate the search space of relationships exponentially increasing according to the number of regulators and genes. This challenge is addressed by the iterative local optimization with regulator-gene interaction knowledge. In this study, I developed a two-step iterative RL-based method to predict n-to-m relationships from regulator and gene expression data. The first step is to explore the n-to-one gene-oriented step that selects regulators by reinforcement learning based heuristic to add edges to the network. The second step is to explore the one-to-m regulator-oriented step that stochastically selects genes to remove edges from the network. In experiments on breast cancer cell line data, the proposed method constructed breast cancer subtype-specific networks from the regulator and gene expression profiles with a more accurate gene expression estimation than previous combinatorial optimization methods. Moreover, regulatory relationships involved in the networks were associated with breast cancer subtypes. In summary, in this thesis, I proposed computational methods for predicting one-to-m, n-to-one, and n-to-m relationships between multi-omics regulators and genes utilizing external domain knowledge. The proposed methods are expected to deepen our knowledge of cellular mechanisms by understanding gene regulatory interactions by analyzing the ever-increasing molecular biology data such as The Cancer Genome Atlas, Cancer Cell Line Encyclopedia.Chapter 1 Introduction 1 1.1 Biological background 1 1.1.1 Multi-omics analysis 1 1.1.2 Multi-omics relationships indicating cell state 2 1.1.3 Biological prior knowledge 4 1.2 Research problems for the multi-omics relationship 6 1.3 Computational challenges and approaches in the exploring multiomics relationship 6 1.4 Outline of the thesis 12 Chapter 2 Literature-based condition-specific miRNA-mRNA target prediction 13 2.1 Computational Problem & Evaluation criterion 14 2.2 Related works 15 2.3 Motivation 17 2.4 Methods 20 2.4.1 Identifying genes and miRNAs based on the user-provided context 22 2.4.2 Omics Score 23 2.4.3 Context Score 24 2.4.4 Confidence Score 26 2.5 Results 26 2.5.1 Pathway analysis 27 2.5.2 Reproducibility of validated targets in humans 31 2.5.3 Sensitivity tests when different keywords are used 33 2.6 Summary 34 Chapter 3 DRIM: A web-based system for investigating drug response at the molecular level by condition-specific multi-omics data integration 36 3.1 Computational Problem & Evaluation criterion 37 3.2 Related works 38 3.3 Motivation 42 3.4 Methods 44 3.4.1 Step 1: Input 45 3.4.2 Step 2: Identifying perturbed sub-pathway with time-series 45 3.4.3 Step 3: Embedding multi-omics for selecting potential mediator genes 47 3.4.4 Step 4: Construct TF-regulatory time-bounded network and identify regulatory path 52 3.4.5 Step 5: Analysis result on the web 52 3.5 Case study: Comparative analysis of breast cancer cell lines that have different sensitivity with lapatinib 54 3.5.1 Multi-omics analysis result before drug treatment 56 3.5.2 Time-series gene expression analysis after drug treatment 57 3.6 Summary 61 Chapter 4 Combinatorial modeling and optimization using iterative RL search for inferring sample-specific regulatory network 63 4.1 Computational Problem & Evaluation criterion 64 4.2 Related works 64 4.3 Motivation 66 4.4 Methods 68 4.4.1 Formulating an objective function 68 4.4.2 Overview of an iterative search method 70 4.4.3 G-step for exploring n-to-one gene-oriented relationship 73 4.4.4 R-step for exploring one-to-m regulator-oriented relationship 79 4.5 Results 80 4.5.1 Cancer cell line data 80 4.5.2 Hyperparameters 81 4.5.3 Quantitative evaluation 82 4.5.4 Qualitative evaluation 83 4.6 Summary 86 Chapter 5 Conclusions 88 국문초록 111박

Network-driven strategies to integrate and exploit biomedical data

[eng] In the quest for understanding complex biological systems, the scientific community has been delving into protein, chemical and disease biology, populating biomedical databases with a wealth of data and knowledge. Currently, the field of biomedicine has entered a Big Data era, in which computational-driven research can largely benefit from existing knowledge to better understand and characterize biological and chemical entities. And yet, the heterogeneity and complexity of biomedical data trigger the need for a proper integration and representation of this knowledge, so that it can be effectively and efficiently exploited. In this thesis, we aim at developing new strategies to leverage the current biomedical knowledge, so that meaningful information can be extracted and fused into downstream applications. To this goal, we have capitalized on network analysis algorithms to integrate and exploit biomedical data in a wide variety of scenarios, providing a better understanding of pharmacoomics experiments while helping accelerate the drug discovery process. More specifically, we have (i) devised an approach to identify functional gene sets associated with drug response mechanisms of action, (ii) created a resource of biomedical descriptors able to anticipate cellular drug response and identify new drug repurposing opportunities, (iii) designed a tool to annotate biomedical support for a given set of experimental observations, and (iv) reviewed different chemical and biological descriptors relevant for drug discovery, illustrating how they can be used to provide solutions to current challenges in biomedicine.[cat] En la cerca d’una millor comprensió dels sistemes biològics complexos, la comunitat científica ha estat aprofundint en la biologia de les proteïnes, fàrmacs i malalties, poblant les bases de dades biomèdiques amb un gran volum de dades i coneixement. En l’actualitat, el camp de la biomedicina es troba en una era de “dades massives” (Big Data), on la investigació duta a terme per ordinadors se’n pot beneficiar per entendre i caracteritzar millor les entitats químiques i biològiques. No obstant, la heterogeneïtat i complexitat de les dades biomèdiques requereix que aquestes s’integrin i es representin d’una manera idònia, permetent així explotar aquesta informació d’una manera efectiva i eficient. L’objectiu d’aquesta tesis doctoral és desenvolupar noves estratègies que permetin explotar el coneixement biomèdic actual i així extreure informació rellevant per aplicacions biomèdiques futures. Per aquesta finalitat, em fet servir algoritmes de xarxes per tal d’integrar i explotar el coneixement biomèdic en diferents tasques, proporcionant un millor enteniment dels experiments farmacoòmics per tal d’ajudar accelerar el procés de descobriment de nous fàrmacs. Com a resultat, en aquesta tesi hem (i) dissenyat una estratègia per identificar grups funcionals de gens associats a la resposta de línies cel·lulars als fàrmacs, (ii) creat una col·lecció de descriptors biomèdics capaços, entre altres coses, d’anticipar com les cèl·lules responen als fàrmacs o trobar nous usos per fàrmacs existents, (iii) desenvolupat una eina per descobrir quins contextos biològics corresponen a una associació biològica observada experimentalment i, finalment, (iv) hem explorat diferents descriptors químics i biològics rellevants pel procés de descobriment de nous fàrmacs, mostrant com aquests poden ser utilitzats per trobar solucions a reptes actuals dins el camp de la biomedicina

Gene Expression Analysis Methods on Microarray Data a A Review

In recent years a new type of experiments are changing the way that biologists and other specialists analyze many problems. These are called high throughput experiments and the main difference with those that were performed some years ago is mainly in the quantity of the data obtained from them. Thanks to the technology known generically as microarrays, it is possible to study nowadays in a single experiment the behavior of all the genes of an organism under different conditions. The data generated by these experiments may consist from thousands to millions of variables and they pose many challenges to the scientists who have to analyze them. Many of these are of statistical nature and will be the center of this review. There are many types of microarrays which have been developed to answer different biological questions and some of them will be explained later. For the sake of simplicity we start with the most well known ones: expression microarrays

Systems Analytics and Integration of Big Omics Data

A “genotype"" is essentially an organism's full hereditary information which is obtained from its parents. A ""phenotype"" is an organism's actual observed physical and behavioral properties. These may include traits such as morphology, size, height, eye color, metabolism, etc. One of the pressing challenges in computational and systems biology is genotype-to-phenotype prediction. This is challenging given the amount of data generated by modern Omics technologies. This “Big Data” is so large and complex that traditional data processing applications are not up to the task. Challenges arise in collection, analysis, mining, sharing, transfer, visualization, archiving, and integration of these data. In this Special Issue, there is a focus on the systems-level analysis of Omics data, recent developments in gene ontology annotation, and advances in biological pathways and network biology. The integration of Omics data with clinical and biomedical data using machine learning is explored. This Special Issue covers new methodologies in the context of gene–environment interactions, tissue-specific gene expression, and how external factors or host genetics impact the microbiome

Explainable artificial intelligence for patient stratification and drug repositioning

Enabling precision medicine requires developing robust patient stratification methods as well as drugs tailored to homogeneous subgroups of patients from a heterogeneous population. Developing de novo drugs is expensive and time consuming with an ultimately low FDA approval rate. These limitations make developing new drugs for a small portion of a disease population unfeasible. Therefore, drug repositioning is an essential alternative for developing new drugs for a disease subpopulation. There is a crucial need to develop data-driven approaches that find druggable homogeneous subgroups within the disease population and reposition the drugs for these subgroups. In this study, we developed an explainable AI approach for patient stratification and drug repositioning. Exploratory mining mimicking the trial recruitment process as well as network analysis were used to discover homogeneous subgroups within a disease population. For each subgroup, a biomedical network analysis was done to find the drugs that are most relevant to a given subgroup of patients. The set of candidate drugs for each subgroup was ranked using an aggregated drug score assigned to each drug. The method represents a human-in-the-loop framework, where medical experts use data-driven results to generate hypotheses and obtain insights into potential therapeutic candidates for patients who belong to a subgroup. To examine the validity of our method, we implemented our method on individual cancer types and on pan-cancer data to consider the inter- and intra-heterogeneity within a cancer type and among cancer types. Patients' phenotypic and genotypic data was utilized with a heterogeneous knowledge base because it gives a multi-view perspective for finding new indications for drugs outside of their original use. Our analysis of the top candidate drugs for the subgroups showed that most of these drugs are FDA-approved drugs for cancer, and others are non-cancer related, but have the potential to be repurposed for cancer. We have discovered novel cancer-related mechanisms that these drugs can target in different cancer types to reduce cancer treatment costs and improve patient survival. Further wet lab experiments to validate these findings are required prior to initiating clinical trials using these repurposed therapies.Includes bibliographical references

Opportunities and obstacles for deep learning in biology and medicine

Deep learning describes a class of machine learning algorithms that are capable of combining raw inputs into layers of intermediate features. These algorithms have recently shown impressive results across a variety of domains. Biology and medicine are data-rich disciplines, but the data are complex and often ill-understood. Hence, deep learning techniques may be particularly well suited to solve problems of these fields. We examine applications of deep learning to a variety of biomedical problems-patient classification, fundamental biological processes and treatment of patients-and discuss whether deep learning will be able to transform these tasks or if the biomedical sphere poses unique challenges. Following from an extensive literature review, we find that deep learning has yet to revolutionize biomedicine or definitively resolve any of the most pressing challenges in the field, but promising advances have been made on the prior state of the art. Even though improvements over previous baselines have been modest in general, the recent progress indicates that deep learning methods will provide valuable means for speeding up or aiding human investigation. Though progress has been made linking a specific neural network\u27s prediction to input features, understanding how users should interpret these models to make testable hypotheses about the system under study remains an open challenge. Furthermore, the limited amount of labelled data for training presents problems in some domains, as do legal and privacy constraints on work with sensitive health records. Nonetheless, we foresee deep learning enabling changes at both bench and bedside with the potential to transform several areas of biology and medicine

Applying machine learning to derive actionable insights in precision oncology

Cancer drugs have among the lowest response rates across all diseases. Combining the wealth of omics data and machine learning is a promising way to reach this goal. In this thesis, we addressed the following aspects of precision oncology: (i) We used Macau, a bayesian multitask multi-relational algorithm to explore the associations between the drugs’ targets and signaling pathways’ activation. We applied this methodology to drug synergy prediction and stratification. (ii) We leveraged through a collaborative machine learning competition to understand the association between genome, transcriptome and proteome in tumors. The main focus of this thesis is to use machine learning to generate actionable insights, for more personalized therapies

Deep transfer learning for drug response prediction

The goal of precision oncology is to make accurate predictions for cancer patients via some omics data types of individual patients. Major challenges of computational methods for drug response prediction are that labeled clinical data is very limited, not publicly available, or has drug response for one or two drugs. These challenges have been addressed by generating large-scale pre-clinical datasets such as cancer cell lines or patient-derived xenografts (PDX). These pre-clinical datasets have multi-omics characterization of samples and are often screened with hundreds of drugs which makes them viable resources for precision oncology. However, they raise new questions: how can we integrate different data types? how can we handle data discrepancy between pre-clinical and clinical datasets that exist due to basic biological differences? and how can we make the best use of unlabeled samples in drug response prediction where labeling is extra challenging? In this thesis, we propose methods based on deep neural networks to answer these questions. First, we propose a method of multi-omics integration. Second, we propose a transfer learning method to address data discrepancy between cell lines, patients, and PDX models in the input and output space. Finally, we proposed a semi-supervised method of out-of-distribution generalization to predict drug response using labeled and unlabeled samples. The proposed methods have promising performance when compared to the state-of-the-art and may guide precision oncology more accurately